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Glioblastoma multiforme is the most invasive and aggressive brain tumor in humans, and despite the latest chemical and radiative
therapeutic approaches, it is still scarcely sensitive to these treatments and is generally considered an incurable disease. This paper
will focus on the latest approaches to the treatment of this cancer, including the new chemicals such as proautophagic drugs
and kinases inhibitors, and diﬀerentiating agents. In this ﬁeld, there have been opening new perspectives as the discovery of
possible speciﬁc targets such as the EGFRvIII, a truncated form of the EGF receptor. Antibodies against these targets can be
used as proapoptotic agents and as possible carriers for chemicals, drugs, radioisotopes, and toxins. In this paper, we review the
possible mechanism of action of these therapies, with particular attention to the combined use of toxic substances (for example,
immunotoxins) and antiproliferative/diﬀerentiating compounds (i.e., ATRA, PPARγ agonists). All these aspects will be discussed
in the view of progress clinical trials and of possible new approaches for directed drug formulations.
1.CellularandMolecularBiology ofGliomas
Malignant gliomas, the most common type of primary
brain tumor, are a spectrum of tumors of varying dif-
ferentiation and malignancy grades. Early genetic events
diﬀer between astrocytic and oligodendroglial tumors, but
all tumors have an initially invasive phenotype that does not
allow simple therapeutic approaches. Progression-associated
genetic alterations are common to diﬀerent tumor types and
target growth-promoting and cell-cycle-controlling path-
ways, resulting in focal hypoxia, necrosis, and angiogenesis.
Mutations in the retinoblastoma protein (Rb) have been
identiﬁed in 20% of malignant gliomas [1] and those lacking
mutations in Rb contain mutations in other molecules
involved in the Rb signaling pathway, such as the cell-cycle
regulator p16INK4A or cyclin-dependent kinase (CDK).
60%–80% of anaplastic astrocytoma contains homozygous
deletion, mutation, and promoter hypermethylation of
the INK4A/ARF locus, and 25% of anaplastic oligoden-
drogliomas have hypermethylation of the INK4A/ARF locus
[2]. In addition, gene ampliﬁcation in gliomas causes the
overexpression of several mitogens and their speciﬁc recep-
tors. These include epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), insulin-like growth factor 1
(IGF-1), and their speciﬁc receptors (EGFR, PDGFR, and
IGFR), all of which are involved in autocrine or paracrine
signaling in gliomas [3–7]. These receptors with tyrosine
kinase activity also exist in constitutively active mutant
forms in gliomas [7], regulating several signaling path-
ways such as phosphoinositide-3-kinase/AKT-protein kinase
B (PI3K/AKT-PKB), RAS/mitogen-activated protein kinase
(MAPK),and phospholipase C/protein kinase C (PLC/PKC).
Thesesignalingpathwayscontrolseveralbiologicalprocesses,
such as cell proliferation, diﬀerentiation, invasion, and
apoptosis [8]. Phosphatase/tensin homolog protein (PTEN),
whichactsasatumorsuppressorbyinhibitingthePI3K/AKT
signaling pathway, can also be involved in gliomagenesis
through loss-of-function mutations [9, 10]. In gliomas,
several overexpressed angiogenic factors, such as ﬁbroblast
growthfactor(FGF),interleukin(IL)-8,PDGF,transforming
growth factor (TGF), and vascular endothelial growth factor
(VEGF), have been identiﬁed. Combined genetic alterations
in these factors result in aggressive cellular proliferation,
invasion, and angiogenesis rendering malignant gliomas
resistant to intensive therapy. Recently, a population of
glioma stem cells has been isolated. This subpopulation
of stem-like cells plays an important role in the tumori-
genic process [11–14]. Because glioma stem cells can self-
propagate, it might also be important to speciﬁcally target
glioma stem cells to avoid recurrence of the glioma [15].2 ISRN Oncology
The possibility to isolate GBM stem cells opens the frontier
of gene replacement, knockdown, or silencing as a new
therapeutic approach [15].
2. Chemotherapy
In standard treatment protocols, brain tumor resection
and radiation therapy are followed by chemotherapy with
drugs causing DNA alkylation, like nitrosoureas. Standard
treatment is a combination of procarbazine, lomustine
and vincristine or carmustine or temozolomide alone [16].
Recently, GLIADEL wafers have been introduced. GLIADEL
wafers are small, dime-sized biodegradable polymer wafers
that are designed to deliver BCNU or carmustine directly
into the surgical cavity created when a brain tumor is
resected. Immediately after a neurosurgeon operates to
remove the high-grade malignant glioma, up to eight wafers
are implanted along the walls and ﬂoor of the cavity that the
tumor once occupied. Each wafer contains a precise amount
of carmustine that dissolves slowly, delivering carmustine
to the surrounding cells. A clinical study was conducted in
240 men and women undergoing surgery for a newly diag-
nosed high-grade malignant (cancerous) glioma [17]. Each
patient was randomly assigned to receive either surgery with
implantation of GLIADEL followed by radiation therapy, or
surgery with implantation of placebo wafers (wafers without
any carmustine) followed by radiation therapy. The results
of this study showed that survival was prolonged in the
patients who received GLIADEL wafers compared to those
who received the placebo wafers; median survival increased
to 13.8 months from 11.6 months. Until recently, the beneﬁt
of chemotherapy following surgery and radiation has been
almost negligible for most GBM patients. Autophagy repre-
sents an alternative tumor-suppressing mechanism to over-
come, at least partly, the dramatic resistance of many cancers
to radiotherapy and proapoptotic-related chemotherapy.
Temozolomide contributes signiﬁcant therapeutic beneﬁts
in glioblastoma patients [18]. Indeed, the addition of
temozolomide to radiotherapy resulted in a longer median
survival time in newly diagnosed glioblastoma patients, 14.6
versus 12.1 months, and a higher 2-year survival rate, 26.5%
versus 10.4% [19]. Part of temozolomide cytotoxic activity is
exerted through proautophagic processes, at least in glioblas-
toma cells, as a result of the formation of O6-methylguanine
in DNA, which mispairs with thymine during the following
cycle of DNA replication [16]. Glioma cells, thus, respond
to temozolomide by undergoing G2/M arrest, but ultimately
diefromautophagy[19,20].KnowingthatO6-alkylguanine-
DNA alkyltransferase (AGT) is a DNA repair enzyme that
limits the eﬃcacy of temozolomide in glioblastoma cells [20]
ﬁrst showed that inhibition of AGT by O6-benzylguanine
can render previously resistant glioblastoma cells sensitive to
temozolomide. The data obtained by Hegi et al. [20] show
that GBM patients with a methylated O6-methylguanine-
DNA methyltransferase (MGMT) promoter beneﬁted from
temozolomide, while those who did not were less responsive.
This case was recently followed up by a randomized, Phase
III study including 573 GBM patients. Patients treated with
temozolomide after radiation had a median survival of 14.6
months as compared to 12.1 months for patients given
radiotherapy alone [20]. These results made this treatment
scheme to become the standard of care for patients with
GBM and approved in USA and Europe for newly diagnosed
GBM. Almost all treated high-grade astrocytoma cases recur
and the tumor usually arises within 2cm of the prior
r e s e c t i o nm a r g i n[ 21]. The current treatment strategies for
recurrent astrocytoma have recently been reviewed [22].
Available therapies following progression are considered
ineﬀective with a progression free survival after six months
(PFS-6) of less than 15%. That is now the commonly used
end point to assess therapeutic activity in clinical oncology
of recurrent glioblastomas [23, 24].
3. NaturalResistance of Glioblastoma
Cells to Apoptosis
Resistance to apoptosis is considered to be a characteristic of
many diverse cancer cells [25]. Defects in apoptosis underlie
not only tumorigenesis but also resistance to cancer treat-
ments [25]. Furthermore, the inherent resistance of cancer
cells to radiotherapy and chemotherapy is mainly due to
changes at genomic, transcriptional, and posttranscriptional
levels of proteins and protein kinases and their transcrip-
tional factor eﬀectors [25]. The phosphatase and tensin
homologue deleted on chromosome ten (PTEN)/phosphat-
idylinositol 3P-kinase (PI3K)/Akt/mammalian target of
rapamycin (mTOR)/nuclear factor kappa B (NF-κB) and
the Ras/Raf/mitogen-activated protein kinase extracellular
signal-related kinase (ERK) kinase (MEK)/ERK signaling
cascades play critical roles in the regulation of gene expres-
sion and in the prevention of apoptosis [26]. Components
of these pathways are mutated or aberrantly expressed in
human cancer (e.g., Ras, B-Raf, PI3K, PTEN, and Akt) [26].
An aberrantly activated PI3K/Akt pathway renders tumor
cells resistant to cytotoxic insults, including those related to
proapoptotic anticancer drugs [26–32]. Deregulation of the
PTEN/PI3K/Akt pathway has been associated with resistance
to chemotherapeutic drugs used in breast cancer, prostate
cancer, ovarian cancer, and malignant gliomas therapy [26–
31]. Shingu et al. [33] have shown, in the context of
glioma cells, that the inhibition of this pathway restores or
even augments the eﬀectiveness of chemotherapy. Preclinical
studies suggested that sensitivity to mTOR inhibitors may
correlate with activation of the PI3K pathway and/or with
aberrant expression of cell-cycle regulatory or antiapoptotic
proteins. mTOR inhibitors are currently under evaluation
in clinical trials and include rapamycin (sirolimus) and
the related derivatives temsirolimus (CCI-779), everolimus
(RAD001), and AP23573 [34] .T h e s et r i a l sh a v es h o w n
that mTOR inhibitors are well tolerated and may induce
prolonged stable disease and tumor regressions in cancer
patients [34]. Apoptosis-based therapies gained interest as
promising experimental treatment strategies, since direct
induction of apoptotic cell death can overcome many of
the classical resistance mechanisms such as activated DNA
repair or detoxiﬁcation. The death ligand TRAIL/Apo2L
might be a useful tool to trigger apoptosis in cancer, since
TRAIL kills tumor cells of diverse cellular origin withoutISRN Oncology 3
severe toxic side eﬀects [35, 36]. However, despite the
common expression of death receptors, not all glioblastoma
cells are susceptible to TRAIL due to intracellular blockage
of apoptotic signalling cascades. Therefore, overcoming
apoptosis resistance becomes an urgent need in order to
sensitize tumors to the actions of death receptor-targeting
therapy. A novel group of peroxisomal proliferator activated
receptor γ (PPARγ) modulating agents sensitize tumor cells
to TRAIL-induced apoptosis [37]. One of these drugs,
troglitazone, is an oral antidiabetes drug, which belongs to
the group of thiazolidinediones. It has been reported that
glioblastoma cells are sensitized to TRAIL-induced apoptosis
by troglitazone via various mechanisms. Troglitazone led
to a marked downregulation of the antiapoptotic proteins
FLIP and survivin. Moreover, in some cell lines, the cell
surface expression of agonistic and antagonistic TRAIL
receptors was altered towards a higher susceptibility to death
receptor induced apoptosis. Troglitazone could counteract
the capability of tumor cells to become resistant to apoptosis
by modulating the apoptotic machinery at diﬀerent levels
[37]. Constitutive activation of the NF-κB pathway also
enables cancer cells to resist cytotoxic insults [38]. These
changes also aﬀect tumor necrosis factor, Fas, and TRAIL
receptors, which play important roles in tumor resistance to
apoptosis during cancer progression [36].
4.Necrosis
While highly resistant to therapeutic apoptotic stimuli, GBM
tumor cells exhibit the paradoxical propensity for extensive
cellular necrosis. Necrosis, in fact, is the most prominent
form of spontaneous cell death in GBM, presented as
foci of necrosis surrounded by broad hypercellular zones
contiguous with normal tissue or by parenchymal inﬁltrates
[39]. While limited blood supply and anoxia due to a
microthromboticprocesshasbeenidentiﬁedasanimportant
causeofnecrosis,themolecularbasisforthisnecroticpheno-
type, particularly in the context of intense apoptotic therapy
resistance, has recently received attention with the discovery
and characterization of the Bcl2-like 12 (Bcl2L12) protein.
Bcl2L12 has been shown to be a potent inhibitor of apoptosis
that is signiﬁcantly overexpressed in primary GBMs [40,
41]. Bcl2L12 is a proline-rich protein characterized by a C-
terminal 14-amino-acid sequence with signiﬁcant homology
with the BH (Bcl-2 Homology) 2 domain found in several
members of the Bcl-2 protein family [37]. RNAi-mediated
knockdown of Bcl2L12 sensitizes human glioma cell lines to
drug-induced apoptosis and reduces tumor formation in an
orthotopic transplant model in vivo [40]. The anti-apoptotic
actions of Bcl2L12 is due to its ability to neutralize eﬀector
caspase activity likely through speciﬁc interaction with eﬀec-
tor caspase-7 [42] .T h e s ea c t i v i t i e so fB c l 2 L 1 2a r er e l e v a n t
to the necrotic process in the light of studies demonstrating
that the suppression of caspase activity redirects the death
program from apoptosis to necrosis [42] suggesting that
post-mitochondrialcaspaseactivationmayactasamolecular
switch between apoptosis and necrosis. In support of this
ﬁndings, germline deletion of post-mitochondrial apoptosis
signaling components, such as the caspase activator Apaf-
1, or blockage of eﬀector caspase by pan-speciﬁc caspase
inhibitors results in decreased apoptosis, with concomitant
increase of necrosis [42]. On this basis, the upregulation of
Bcl2L12asanovelregulatoroftheapoptosis/necrosisbalance
in glial cells may represent an important event in malignant
glioma pathogenesis.
5.AlteredPathwaysandTargeted
Therapies for Gliomas
5.1. Growth Factor Pathways. Platelet-derived growth factor
(PDGF) and epidermal growth factor (EGF) are ligands
for tyrosine kinase receptors with crucial roles in brain
tumor development. Other growth factors involved in brain
tumors are insulin-like growth factors, IGFs [43] ﬁbroblast
growth factor 2, FGF2 [44], ciliary neurotrophic factor,
CNTF [45], hepatocyte growth factor/scatter factor, HGF/SF
[46], vascular endothelial growth factor, VEGF [47], and
transforming growth factor-β,T G F - β [48, 49]. The most
studied is the epidermal growth factor receptor (EGFR)
that was early recognized in gliomas [50, 51]. PDGF is
also a mitogen of neural stem cells of embryonic [52]a n d
adult [53] origin. Analysis of expression of PDGF ligands
and receptors in human gliomas suggests that there is an
autocrine stimulatory loop in almost all gliomas [54].
5.2. EGFR Targeting. Concerning the epidermal growth fac-
t o rr e c e p t o r( a l s ok n o w na sE r b B 1o rH E R 1 ) ,i su s u a l l yo v e r -
activated in most human tumors, and particularly in gliomas
mostly due to gene ampliﬁcation [4, 51, 55, 56] leading to
a marked enhancement of cellular motility, invasion, and
proliferation. It is a transmembrane protein of 170kDa
containing three diﬀerent domains: one that is responsible of
the binding of the growth factor (EGF) on the extracellular
side, one that is a transmembrane lipophilic domain, and an
intracellular tyrosine kinase domain. The activation of the
receptor upon binding of the ligand requires its dimerization
causing a molecular structural rearrangement inducing
cross-phosphorylation of the two intracellular domains on
sitesmainlylocatedattheC-terminus oftheprotein[57,58].
This process leads to the activation of downstream signaling
pathways, which involve several kinases and particularly the
eﬀectors mTOR and MAPK. Inhibitors of these enzymes
have been produced and tested in several clinical trials. The
most studied are inhibitors of the tyrosine kinase activity of
EGFR, such as geﬁtinib [59, 60] and erlotinib [59–65]. Their
action is due to competition with ATP in the catalytic site
of the tyrosine kinase domain, and hence, the inhibition of
the downstream phosphorylation activities. Their degree of
success was relatively low and heterogeneous if compared
with the same treatment in other cancer forms, that is, lung
cancer [66]. A very promising and interesting evolution of
theEGFRtargetingisduetothediscoverythatmanyformsof
glioblastoma express several splicing variants of the receptor,
among which the most represented is that called EGFRvIII
lacking a portion of the extracellular domain corresponding
to exons 2–7, giving rise to a protein of 145kDa [67, 68].
This receptor variant is constitutivelydimerized, and hence4 ISRN Oncology
auto-phosphorylated and active, and not able to bind the
extracellular ligands. Other forms of mutant receptors for
EGF have been described, due to abnormally spliced pro-
ducts or sometime to exon duplications [67, 68]. The
spliced products result in the formation of new inter-exon
boundaries that represent unique sites diﬀerentiating these
receptor forms from the wt receptor. In particular EGFRvIII
shows a glycine residue at the joining point between exons
1 and 8 that is not present in the wt EGFR. So, the EGFR
variants are one of the few examples of glioma-speciﬁc
targets available for directed therapies. The expression of
the variant form vIII seems to be correlated with an
increase of tumorigenicity [69], as demonstrated by the fact
that transformants obtained by introducing copies of the
EGFRvIII in U87MG human and N6 mouse cells allow
these cells to develop and proliferate in nude mice, with
a consistent decrease of apoptosis [70, 71]. The increased
tumorigenic activity of the mutant EGFRvIII has been
associated with an increase of activation of Ras-GTP [71, 72]
and PI 3-kinase [73] as well as the cJun terminal kinase
(JNK), [74], while the reduction of apoptosis has been
linked to an upregulation of BclXL [75]. Inhibitors of PI 3-
kinase such as wortmannin and LY294002 [73] decreased
the transforming activity of EGFRvIII positive cell lines
and decreased the activation of JNK, thus suggesting that
EGFRvIII acts primarily through the activation of PI 3-
kinase/JNK. Therefore, these pathways are expected to be
a possible therapeutic target for speciﬁc inhibitors. Since
EGFRvIII is tumor speciﬁc, some groups have developed
antibodies raised against the extracellular domain, and par-
ticularlytothejunctionbetweenexons1–8thatisnotpresent
in the wt receptor [76, 77]. Monoclonal antibodies with a
good aﬃnity [78] and single chain fragments [78, 79]h a v e
been described; the binding of most of these antibodies to
EGFRvIII positive cells rapidly induces the receptor internal-
ization, thus oﬀering a potential tool to introduce drugs into
cancer cells. Recombinant single chain antibodies (MR1),
from a murine phage display library [80], were isolated by
selection against a synthetic peptide containing the joining
aminoacidic sequence at the boundary of exons 1–8 spliced
product.Thissinglechain[80,81]wasengineeredandlinked
to pseudomonas exotoxin A, producing an immunotoxin
that is greatly active against glioblastoma cells. After aﬃnity
maturation, the scFv-based immunotoxin was more eﬃcient
against glioblastoma cells [82]. Recently, [81]i th a sb e e n
demonstrated that an MR1-based immunotoxin containing
PE38-KDEL (a truncated version of pseudomonas exotoxin)
is able to induce antitumor immunity against the mutated
EGFRvIII, notwithstanding its cytotoxic activity against
EGFRvIII-positive cells, also in EGFRvIII-negative cells,
and that this immunization process is dependent on the
presence of CD8+ and CD4+ T cells [83]. Furthermore,
antibodies raised against EGFRvIII have been used to target
glioblastoma cells, as in the case of the MoAb L8A4 [80]o r
the scFv MR1-1 [77] radiolabeled with 125I. As EGFRvIII-
directed antibodies rapidly induce the internalization of the
receptor-antibody complex, some modiﬁcations have been
suggested to allow retention of the radiolabeled antibody
inside and the cell, using polycationic peptides added to the
aminoacidic sequence of these molecules capable of trapping
theminsidelysosomes.Theincreaseofcellularretentionmay
be helpful for the action of the radioisotope in intoxicating
the cells [84]. Very recently, an antibody against EGFRvIII
was used to deliver iron oxide nanoparticles against model
U87 glioblastoma cells [85]. These derivatized nanoparti-
cles were used for MRI contrast enhancement and CED
(convection-enhanced delivery) therapy, and signiﬁcantly
reduced the size of intracranial human xenograft tumors
and prolonged the life of treated animals. Finally, it should
be cited as a new therapy approach the possibility to
induce immune responses against the EGFRvIII (reviewed
by [85, 86]). This approach started by using immunogenic
peptides corresponding to a 14mer including the boundary
sequence between exons 1 and 8 [86] injected into mice
as a complex with adjuvants, or the recombinant complete
EGFRvIII expressed on the surface of mammalian (300.19
mouse cell line, [87]) cells. In both cases, animals were
protected from the insertion and spreading of the injected
tumor cells expressing EGFRvIII, being the protective eﬀect
due to the presence of CD8+ and CD4+ T cells. Peptides
from EGFRvIII could be also used to induce dendritic cell-
(DC-) mediated immunization [87, 88] when these cells
were treated with an extract of EGFRvIII-transfected cells.
Since it has been shown that is possible to isolate DC from
the peripheral blood of glioma patients, this could open a
concrete possibility to apply combined therapies including
DC vaccination for the treatment of glioblastoma in man.
Furthermore,recently,afusionproteinEGFRvIII-HBcAghas
been used to achieve immune response in BALB/c mice, with
a signiﬁcant increase of the production of INF-γ-secreting
lymphocytes [89] and remarkable resistance to tumor
implantation.
5.3.PDGFTargeting. Platelet-derivedgrowthfactorsarefour
diﬀerent polypeptide chains (A to D) that are recognized
by two types of receptor (PDGFRα and β). The binding of
PDGF to its receptor induces an activation process very simi-
lar to that described for EGFR, with receptor dimerization,
autophosphorylation, and transduction of signals through
the Ras-MAPK, Pi 3Kinase, Src, Stat, and phospholipase C.
The overexpression of PDGF and PDGFR is common in
secondary glioblastomas [90] apparently due to the decrease
of expression of the tumor suppressor TP53. At the moment,
this receptor has been scarcely targeted and mainly by the
use of tyrosine kinase inhibitors, such as imatinib, that are
not speciﬁc to PDGFR and possibly act diﬀerently to what
observed for EGFR inhibitors, by binding in the proximity
of the catalytic site, thus blocking the interaction of protein
kinases with their substrates. This inhibitor blocks the activ-
ityofseveralkinasesincludingbcr-ablandc-kitandhasbeen
approved for chronic myeloid leukaemia and gastrointestinal
tumors, but it proved scarcely eﬀective against gliomas in a
phase II trial against grade III gliomas that should be highly
dependent on PDGFR [91]. This failure has possibly been
attributed to a scarce penetration of the drugs inside the
t u m o rm a s so rt oar e d u c e dr o l eo fP D G Fi ns u c ha d v a n c e d
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5.4. VEGFR Targeting. Vascular endothelial growth factor
A is a member of VEGF family and acts with its receptor
in tumor angiogenesis, a very complex phenomenon that
passes through several steps including the disrupture of the
basal membrane, the increase in proliferation of endothelial
cells, the interaction between cells and the matrix, and
the mobilization of endothelial cells and hematopoietic
progenitors [92]. The action of VEGF also induces the
expression of other proangiogenic factors such as the
urokinase-type plasminogen activator and its overexpressed
receptor and metalloproteinase-1. VEGFRs involved in the
cellular response to VEGF-A are the forms 1 and 2 (Flt-
1 and Flt-2/KDR). VEGFR-2 is a tyrosine kinase inducing
signalling via Ras/Raf/MEK/MAPK and PI3K/AKT/PKB
and proteine kinase C-pathways. Also, for this receptor,
some kinase inhibitors have been tested such as vata-
lanib(PTK787/ZK222584),sorafenib(BAY43-9006),sutinib
(SU11248), and cediranib (AZD2171). All these inhibitors,
although active on glioblastoma cells, proved again relatively
eﬃc i e n td u r i n gt e s to np h a s eI It r i a l s[ 93, 94]. More promis-
ing is the targeting of VEGFR with a speciﬁc humanized
monoclonal antibody (bevacizumab) in combination with
irinotecan [95–97] that gave a high response into patients
with a consistent reduction of the tumor mass although the
overall survival was not greatly enhanced, suggesting that
blocking cell proliferation and tumor mass reduction are not
suﬃcient to counteract the disease. Further, very recently
a novel therapeutic approach has been proposed, targeting
the VEGFR expression via the introduction of an artiﬁ-
cial transcriptional regulator (Zinc ﬁnger, [98]) eventually
mediated by an adenovirus [93], inducing a downregulation
of VEGFR by acting on the VEGFR promoter, resulting in
marked antitumor eﬀect on a human glioblastoma xenograft
model. Finally, it should be cited among the unconventional
therapies the possibility to target VEGFR by a fusion protein,
VEGF121-rGel [99], containing the ribosome inactivating
protein gelonin as a cytotoxic agent.
5.5. Other Possible Targets. In the framework of targeted
toxicity towards glioblastoma, it is worth citing several
immunotoxins that have been made fusing growth factors
such as interleukins 4 and 13, urokinase and transferrin with
toxins. These approaches are mainly based on the fact that
receptors for these substances are not or are very poorly
expressed in normal brain tissues. Historically transferrin-
based immunotoxins have been produced by fusion with
diphtheriatoxinmutants(CRM107,[100])thatresultedvery
eﬀective in reducing tumor mass in the brain after direct
infusionofthetoxin.Thehighresponsetotheimmunotoxin,
as in the case of other chimeras containing toxins, is due
to the rapid and eﬃcient internalization of the receptors
allowing the toxic molecule to be released inside the cell
cytoplasm, where the enzyme activity can be obtained (most
of the toxins used are protein synthesis inhibitors and thus
mustreachribosomes).Oneofthepossibleobstaclesinusing
transferrin-based immunotoxin could be the competition of
free transferrin in the serum that could be overcome by the
use of monoclonal antibodies raised against the transferrin
receptor that do not recognize epitopes in the ligand-
binding domain [100]. Many gliomas and particularly GBM
overexpresstheIL4receptor,thusprovidingagoodcandidate
for the targeting with fusion immunotoxins and indeed very
eﬃcient targeting has been reached by intratumoral infusion
of a circularly permuted IL4 fused to the catalytic domain
of pseudomonas exotoxin (PE38KDEL, [101]). In this study,
progressive and massive necrosis of the tumor masses
were observed, with a signiﬁcant increase of the survival
expectation and one case of complete remission lasting over
a 18 month period. IL4 receptor overexpression has been
then conﬁrmed in many other brain tumors [102] making
this receptor a good general target for this pathological
tissues. Interestingly, IL4 receptor, as well as transferrin
receptor, expression is enhanced (from 25% to 45% with
respect to the control, [103]) upon radiation therapy, thus
suggesting a possible application of both radio- and toxin-
based therapies for the treatment of glioblastoma. Along
the same framework of interactions between IL receptors, it
has been described in glioblastoma cells the presence of a
variant of IL13 receptor (IL13R2, [104]) that is not present
on normal brain tissues. The fusion toxin between IL13 and
atruncatedformofpseudomonasexotoxinprovedtobevery
eﬃcient in killing glioblastoma cells in culture [105, 106]
and in human xenografts on nude mice [107]. Furthermore,
a mutated form of human IL13 has been engineered to
bind the IL13R2 with very high aﬃnity with respect to
wt IL13R, thus allowing the creation of new fusion toxins
[108] practically devoid of any aspeciﬁc toxicity. IL13-based
toxin have been introduced into clinical trials [108]a n d
demonstrated to be eﬀective in inducing tumor necrosis.
Finally, the urokinase-type plasminogen activator receptor
representsagoodcandidatefortargetedtherapies[109,110],
this receptor being fundamental for the activation of invasive
processes. A very promising and interesting immunotoxin
has been created by the fusion of the IL13 molecule with
the N-terminal fragment of human urokinase (ATF) and the
toxicandtranslocationdomainsofdiphtheriatoxin(DTAT3,
[111]), able to induce complete killing of small tumors in
mouse xenograft models.
6. Differentiating and Proapoptotic Therapies
6.1. Retinoic Acid. All transretinoic acid (ATRA) is an
important modulator of multiple biological processes [112].
IthasbeenshownthatATRAinducesmorphologicalchanges
well-matched with diﬀerentiation, suppresses proliferation,
and even causes apoptosis in some tumor cells, includ-
ing glioblastoma cells [113–115]. In tumor cells, ATRA
treatment may result in increases in p21, p27, and p53
protein levels and cell-cycle arrest at G1 phase, which also
correlates with signiﬁcant downregulation of cell surface
Her2/neu oncoprotein expression [112, 115]. It is well
documented that downregulation of cell surface Her2/neu
expression reverses transformed phenotypes and leads to
a reduction in proliferation of tumor cells. Treatment of
tumors with ATRA has been shown to exhibit increased
sensitivity to MHC class I-restricted killing by CTL and
NK-cell-mediated lysis [116, 117]. ATRA has also been
shown to be beneﬁcial in leukemia, cervical cancer, thyroid6 ISRN Oncology
cancer, breast cancer, squamous cell carcinoma, skin cancer,
and head and neck cancer when administered alone or in
combination with other therapies [118]. Moreover, ATRA
may induce the expression of proteolytic and regulatory
subunits of the immunoproteasome, increase the half-life
of MHCclass I complexes, and enhance the sensitivity of
tumor cells to both MHC class I-restricted peptide-speciﬁc
and MHC nonrestricted lysis by CTL, NK, and NK T-
cells [119–121]. ATRA also induces systemic modulation of
antigen presentation by nonprofessional antigen presenting
cells such as tumor cells. In addition, ATRA has been shown
to modify the immunogenicity of tumor cells both in vitro
and in vivo through diﬀerential regulation of MHC class I
and intercellular adhesion molecule-1 (ICAM-1) [114, 117].
The upregulation of ICAM-1 may increase the sensitivity of
glioblastomatoNK-cells.Studiessuggestthattumorcellscan
be converted to eﬃcient antigen presenting cells for direct
antigen presentation and T-cell stimulation [120]. It has
been has shown that IFN-γ is an important biomolecule for
positive regulation of the MHC presentation machinery. The
treatment of glioblastoma cells with IFN-γ induces apoptosis
and the extent of cell death is enhanced by pretreatment with
ATRA. It was also showed that a combination of ATRA and
IFN-γ expressed higher levels of HLA class II and HLA-DM
molecules in glioblastoma T98G and U87MG cells than IFN-
c alone [121], suggesting that the combination of ATRA with
INF-γ may overcome the defect in class II-mediated immune
recognition of glioblastoma [121].
6.2. PPARγ Agonists. T h ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e d
receptors (PPARs) are a subgroup of ligand-activated tran-
scription factors. They belong to the nuclear receptor
family. Other members of this family include steroid and
thyroid hormone receptors, retinoid receptors, and vitamin
Dr e c e p t o r s[ 122]. The PPAR family comprises three closely
related gene products, PPARα, β/˜ o, and γ. All have a
highly conserved structure [122]. PPARγ activation plays a
role in diverse physiological and pathophysiological events
including stimulation of adipocyte diﬀerentiation, activation
of insulin, regulation of lipid metabolism, inhibition of
tumor cell proliferation, and diverse eﬀects on inﬂammatory
processes [122]. Endogenous PPARγ ligands are polyunsat-
urated fatty acids and eicosanoids, such as 15-deoxy-delta
12,14-prostaglandin J2 and leukotriene B4. A number of
synthetic PPARγ ligands have been identiﬁed over the past
7 years, of which the most well known are the thiazolidine-
diones (TZDs) (pioglitazone, ciglitazone, rosiglitazone, etc.).
TZDs are a class of antidiabetic agents that improve insulin
sensitivity and reduce plasma glucose and blood pressure
in patients with type2 diabetes mellitus [122]. It is well
known that the response of tumor cells to antiproliferative
treatments is strongly dependent on their diﬀerentiation
degree. PPAR not only plays a crucial role in apoptosis but
also in diﬀerentiation of a variety of cell types, including
malignant cells (since induction of diﬀerentiation through
PPARactivationhasbeenobservedinseveralmalignantcells;
[123–125]. Several studies have reported antiproliferative
and/or diﬀerentiating activities of some lipophilic molecules
onglioblastomacells.Someoftheseactivitiesincellsignaling
are mediated by PPARs [126]. PPAR has been identiﬁed in
transformed neural cells of human origin, and it has been
demonstrated that PPAR agonists decrease cell proliferation,
stimulate apoptosis and induce morphological changes and
expression of markers typical of a more diﬀerentiated
phenotype in glioblastoma and astrocytoma cell lines [127].
These ﬁndings arise from studies mainly performed on long-
term cultured transformed cell lines and more recently also
in glioblastoma primary cultures. It has been reported that
PPARγ natural and synthetic ligands may interfere with
glioblastoma growth and malignancy and might be taken
i na c c o u n ta sn o v e la n t i t u m o r a ld r u g s .I nf a c t ,t r e a t m e n t s
with natural or synthetic ligands of PPARγ decreases the
expression of undiﬀerentiating markers such as CD133,
nestin, and ﬁbronectin while increasing the expression of
diﬀerentiation markers such as A2B5, GFAP, β-catenin, and
N-cadherin. CLA and PPARγ agonist suppress proliferation
and induce apoptosis in primary cultures of glioblastoma
cells [128]. Consistently with growth inhibition, both lig-
ands downregulate cyclinD1and CDk4 protein levels, while
inducing the transcription of the tumor suppressor gene
PTEN. Besides being utilized for glioma histological char-
acterization, astroglial marker GFAP is also recognized as
an indicator of glioma diﬀerentiation, since its expression
increases upon several anticancer drug treatments [128].
CLA and PPARγ synthetic agonist induced a signiﬁcant
increase of GFAP protein levels as well as the acquirement
of the astrocytic phenotype indicating that activated-PPARγ
induces diﬀerentiation of glioblastoma cells. Both CLA and
PPARγ agonist treatments led to a signiﬁcant decrease of
the VEGF isoforms and NOSII, thus indicating that even
in glioblastoma, PPARγ is able to inhibit the angiogenetic
pathways [128]. The overall, the data in the literature point
towards the possibility to use PPARγ ligands in the treatment
of malignant gliomas and their recurrence.
6.3. Autophagic Drugs. Proautophagic drugs are a promising
class of compounds in counteracting tumor progression by
favouring cell death [129–131]. A variety of chemical or
physical treatments, including rapamycin (mTOR inhibitor)
[132–134], arsenic trioxide [135], ceramide [136], temozolo-
mide [137, 138], dopamine [139], endostatin [140], the his-
tone deacetylase (HDAC) inhibitors butyrate and suberoy-
lanilidehydroxamicacid[141],neodymiumoxide[142],and
resveratrol [143], have been reported to induce autophagy in
vitro and in vivo in certain cancer cells. Rapamycin and its
analogues (such as CCI-779, RAD001, and AP23573) inhibit
mTOR, the kinase that normally suppresses both apoptosis
and autophagy and that is active when nutrients are abun-
dant.Rapamycinactivatestheautophagicprocess[129–131],
and the inhibition of autophagy by small interfering RNA
(siRNA), directed against the autophagy-related gene beclin
1, attenuates the cytotoxicity of rapamycin in rapamycin-
sensitive tumor cells, indicating that autophagy is a primary
mediator of rapamycin-mediated antitumor eﬀects rather
than a protective response [144]. Exogenous expression of an
mTORmutant, interfering with its kinase activity, markedly
enhances the incidence of rapamycin-induced autophagy
[144]. Importantly, not only rapamycin-sensitive malignantISRN Oncology 7
glioma cells but also rapamycin-resistant malignant glioma
cells with wild-type PTEN are sensitized to rapamycin by
mTOR siRNA [144]. In addition, mTOR inhibitors sensitize
tumor cells to DNA-damaging agents in vitro [134].
7. FutureDirections inGlioma Therapy
The progress and depth of understanding of the biology
and genetics of glioma, together with truly manipulable
experimental models, now oﬀer very real opportunities
for the development of eﬀective targeted therapy. These
new approaches will, in the future, integrate the current
experimental therapies. Despite signiﬁcant gaps in our
understanding, a wealth of information now exists about the
clinical and biological behavior of the tumors, the genetic
pathways involved in gliomagenesis, and the nature and role
of signature alterations in these pathways. The challenge now
is to integrate all of this knowledge in an interdisciplinary
way to fully understand this disease and how its signature
heterogeneity contributes to its intractability.
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